Calmark receives order from India

Calmark receives order from India

Press releases
Calmark Sweden AB (publ) announces today that an order for 50 instruments and 2,000 test cassettes relating to the Calmark Neo-Bilirubin product has been received from the Company's distributor in India, r2 Diagnostics. The registration process in India for the products is ongoing and is anticipated to be completed shortly.

Today's order comprises 50 instruments with associated test cassettes to be dispatched to end customers in selected children’s hospitals in India according to a release plan. The order will be delivered as soon as the registration process is completed.

“I am very pleased that things are under way in the vast and important market of India. The fact that this order arrives before the registration process is fully completed shows that the distributor is committed and really eager to shorten the time-to-delivery for customers,” says Magdalena Tharaldsen, Calmark’s Director International Business Development. “Approximately 25 million children are born every year in India, and the market for bilirubin blood tests exceeds 7.5 million tests.”

This information is information that Calmark Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (Regulation (EU) No 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 08:38 CEST on 19 August 2022

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.